<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00118131</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000433488</org_study_id>
    <secondary_id>P30CA072720</secondary_id>
    <secondary_id>CINJ-030302</secondary_id>
    <secondary_id>CINJ-NJ1503</secondary_id>
    <nct_id>NCT00118131</nct_id>
  </id_info>
  <brief_title>Docetaxel and Cisplatin in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer</brief_title>
  <official_title>Phase II Study of Weekly Docetaxel Together With Weekly Cisplatin in Chemotherapy-Naive Patients With Stage IV or Select Stage IIIB (Malignant Effusion) Non-Small Cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Medicine and Dentistry of New Jersey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>Aventis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Rutgers, The State University of New Jersey</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as docetaxel and cisplatin, work in different
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from
      dividing. Giving more than one drug (combination chemotherapy) may kill more tumor cells.

      PURPOSE: This phase II trial is studying how well giving docetaxel together with cisplatin
      works in treating patients with stage III or stage IV non-small cell lung cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the antitumor activity of docetaxel and cisplatin, as measured by tumor
           response rate, in patients with chemotherapy-naïve stage IIIB or IV non-small cell lung
           cancer.

      Secondary

        -  Determine the duration of response in patients treated with this regimen.

        -  Determine time to disease progression in patients treated with this regimen.

        -  Determine the 1-year survival rate in patients treated with this regimen.

        -  Determine the median survival time in patients treated with this regimen.

        -  Correlate aneuploidy (as determined by DNA histograms) and immunohistochemical
           expression of stathmin, Aurora-A, and survivin with response in patients treated with
           this regimen.

      OUTLINE: This is an open-label, nonrandomized, multicenter study.

      Patients receive docetaxel IV over 1 hour and cisplatin IV over 1 hour once on days 1, 8, and
      15. Treatment repeats every 28 days for up to 6 courses in the absence of disease progression
      or unacceptable toxicity.

      After completion of study treatment, patients are followed every 6 months.

      PROJECTED ACCRUAL: A total of 76 patients will be accrued for this study within 13-19 months.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Slow accrual
  </why_stopped>
  <start_date>December 2003</start_date>
  <completion_date type="Actual">February 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall Tumor Response Rate</measure>
    <time_frame>7 years</time_frame>
    <description>Patients experiencing complete or partial response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to Progressive Disease</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1-year Survival Rate</measure>
    <time_frame>8 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median Survival Time</measure>
    <time_frame>10 years</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Docetaxel and Cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <arm_group_label>Docetaxel and Cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>docetaxel</intervention_name>
    <arm_group_label>Docetaxel and Cisplatin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically or cytologically confirmed non-small cell lung cancer, meeting 1 of the
             following stage criteria:

               -  Stage IIIB disease with malignant pericardial or malignant pleural effusions, as
                  indicated by 1 of the following:

                    -  Positive cytology

                    -  Exudative effusion AND lactic dehydrogenase (LDH) &gt; 200 IU with
                       effusion/serum LDH ratio ≥ 0.6

               -  Stage IV disease

          -  Measurable disease, defined as ≥ 1 unidimensionally measurable lesion &gt; 20 mm by
             conventional techniques OR &gt; 10 mm by spiral CT scan

          -  Brain metastases allowed provided they have been irradiated AND are radiographically
             stable for ≥ 28 days after the completion of radiotherapy

        PATIENT CHARACTERISTICS:

        Age

          -  18 and over

        Performance status

          -  ECOG 0-1

        Life expectancy

          -  At least 12 weeks

        Hematopoietic

          -  Absolute neutrophil count ≥ 1,500/mm^3

          -  Platelet count ≥ 100,000/mm^3

          -  Hemoglobin ≥ 8.0 g/dL

        Hepatic

          -  AST and ALT normal

          -  Bilirubin normal

        Renal

          -  Creatinine clearance ≥ 50 mL/min

        Immunologic

          -  No known HIV positivity

          -  No history of severe hypersensitivity reaction to docetaxel or other drugs formulated
             with polysorbate 80

          -  No clinically significant active infection

        Other

          -  Not pregnant or nursing

          -  Fertile patients must use effective contraception before, during, and for 4 weeks
             after completion of study treatment

          -  No other primary malignancy within the past 5 years except adequately treated
             nonmelanoma skin cancer or carcinoma in situ of the cervix

          -  No other serious systemic disorder that would preclude study participation

          -  No other condition that would preclude study compliance

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Prior antibody-based therapy that targets growth factor pathways (e.g., epidermal
             growth factor receptor [EGFR]) allowed provided there is disease progression during
             therapy and patient has recovered

          -  No concurrent immunotherapy

          -  No concurrent prophylactic colony-stimulating factors

          -  No concurrent interleukin-11

        Chemotherapy

          -  No prior cytotoxic chemotherapy

          -  No other concurrent chemotherapy

        Endocrine therapy

          -  No concurrent hormonal therapy for the malignancy

        Radiotherapy

          -  See Disease Characteristics

          -  More than 28 days since prior radiotherapy and recovered

          -  No prior radiotherapy to ≥ 25% of the bone marrow

          -  No prior radiotherapy to sites of measurable disease unless there is documented tumor
             progression after completion of radiotherapy

          -  No concurrent radiotherapy

        Surgery

          -  No concurrent surgery for the malignancy

        Other

          -  More than 3 weeks since prior investigational drugs

          -  Prior oral small molecule drug therapy that targets growth factor pathways (e.g.,
             EGFR) allowed provided there is disease progression during therapy and patient has
             recovered

          -  No other concurrent investigational or commercial agents or therapies for the
             malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joseph Aisner, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rutgers Cancer Institute of New Jersey</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Central Jersey Oncology Center, PA - East Brunswick</name>
      <address>
        <city>East Brunswick</city>
        <state>New Jersey</state>
        <zip>08816</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JFK Medical Center in Edison</name>
      <address>
        <city>Edison</city>
        <state>New Jersey</state>
        <zip>08818</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CentraState Medical Center</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at Hamilton</name>
      <address>
        <city>Hamilton</city>
        <state>New Jersey</state>
        <zip>08690</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Monmouth Medical Center</name>
      <address>
        <city>Long Branch</city>
        <state>New Jersey</state>
        <zip>07740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mountainside Hospital Cancer Center</name>
      <address>
        <city>Montclair</city>
        <state>New Jersey</state>
        <zip>07042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jersey Shore University Medical Center</name>
      <address>
        <city>Neptune</city>
        <state>New Jersey</state>
        <zip>07754</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute of New Jersey at UMDNJ - Robert Wood Johnson Medical School</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Peter's University Hospital</name>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <zip>08903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMDNJ - University Hospital</name>
      <address>
        <city>Newark</city>
        <state>New Jersey</state>
        <zip>07103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Raritan Bay Medical Center</name>
      <address>
        <city>Perth Amboy</city>
        <state>New Jersey</state>
        <zip>08861</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Somerset Medical Center</name>
      <address>
        <city>Somerville</city>
        <state>New Jersey</state>
        <zip>08876</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Overlook Hospital</name>
      <address>
        <city>Summit</city>
        <state>New Jersey</state>
        <zip>07901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 8, 2005</study_first_submitted>
  <study_first_submitted_qc>July 8, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 11, 2005</study_first_posted>
  <results_first_submitted>September 19, 2013</results_first_submitted>
  <results_first_submitted_qc>September 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 25, 2013</results_first_posted>
  <last_update_submitted>September 19, 2013</last_update_submitted>
  <last_update_submitted_qc>September 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage IIIB non-small cell lung cancer</keyword>
  <keyword>stage IV non-small cell lung cancer</keyword>
  <keyword>recurrent non-small cell lung cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Docetaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited from the Cancer Institute of New Jersey (a comprehensive cancer center) and 4 affiliate community hospitals part of the Cancer Institute of New Jersey Oncology Group from December 2003 through February 2008.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Docetaxel and Cisplatin</title>
          <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="49"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Docetaxel and Cisplatin</title>
          <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="49"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Overall Tumor Response Rate</title>
        <description>Patients experiencing complete or partial response</description>
        <time_frame>7 years</time_frame>
        <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Cisplatin</title>
            <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Tumor Response Rate</title>
          <description>Patients experiencing complete or partial response</description>
          <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
          <units>Response rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Progressive Disease</title>
        <time_frame>8 years</time_frame>
        <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Cisplatin</title>
            <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Progressive Disease</title>
          <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.38" lower_limit="2.3" upper_limit="5.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1-year Survival Rate</title>
        <time_frame>8 years</time_frame>
        <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Cisplatin</title>
            <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>1-year Survival Rate</title>
          <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
          <units>1-year survival rate (percentage)</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Median Survival Time</title>
        <time_frame>10 years</time_frame>
        <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
        <group_list>
          <group group_id="O1">
            <title>Docetaxel and Cisplatin</title>
            <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
          </group>
        </group_list>
        <measure>
          <title>Median Survival Time</title>
          <population>Analysis was performed on the first 47 patients only as it was too early to collect data for the last 2 patients.</population>
          <units>months</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.1" lower_limit="5.8" upper_limit="14.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Docetaxel and Cisplatin</title>
          <description>A cycle is defined as an interval of 28 days.
Docetaxel, 35 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 105 mg/m2).
Cisplatin, 25 mg/m2 per day on Days 1, 8 and 15 (total dose for this cycle = 75 mg/m2).
Docetaxel is always to be given prior to cisplatin on Days 1, 8 and 15.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Leukocytes</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Supraventricular arrhythmias (SVT/atrial fibrillation/flutter</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Seizure(s)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Confusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pneumonitis/pulmonary infiltrates</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other (Specify, RLL pneumonia)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other (Specify, respiratory distress)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Thrombosis/embolism - pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (3.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="49" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Leukocytes (total WBC)</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Blood/Bone Marrow-Other (Specify,_____)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neutrophils/granulocytes (ANC/AGC)</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemoglobin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hemoptysis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Ocular/Visual-Other (Specify,___)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Tearing (watery eyes)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhea patients without colostomy</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="26" subjects_affected="19" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="18" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Taste disturbance (dysgeusia)</sub_title>
                <counts group_id="E1" events="19" subjects_affected="15" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="12" subjects_affected="9" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Stomatitis/pharyngitis (oral/pharyngeal mucositis)</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dyspepsia/heartburn</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Gastrointestinal-Other (Specify,_____)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue (lethargy, malaise, asthenia)</sub_title>
                <counts group_id="E1" events="29" subjects_affected="25" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Weight loss</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Fever (in the absence of neutropenia, where neutropenia is defined as AGC&lt;1.0 x 10e9/L)</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pain-Other (Specify,___)</sub_title>
                <counts group_id="E1" events="13" subjects_affected="10" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Allergic reaction/hypersensitivity (including drug fever)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infection without neutropenia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Hypomagnesemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyponatremia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hypokalemia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Hyperglycemia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia (muscle pain)</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Neuropathy-sensory</sub_title>
                <counts group_id="E1" events="16" subjects_affected="12" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="9" subjects_affected="6" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dizziness/lightheadedness</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Neuropathy - motor</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mood alteration-anxiety, agitation</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Mood alteration-depression</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Creatinine</sub_title>
                <counts group_id="E1" events="7" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Renal/Genitourinary-Other (Specify,____)</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnea (shortness of breath)</sub_title>
                <counts group_id="E1" events="25" subjects_affected="19" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Pulmonary-Other (Specify,___)</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatology/Skin-Other (Specify,_____)</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Nail changes</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Rash/desquamation</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis/embolism</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="49"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <counts group_id="E1" events="11" subjects_affected="9" subjects_at_risk="49"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Joseph Aisner</name_or_title>
      <organization>Cancer Institute of New Jersey</organization>
      <phone>732-235-8675</phone>
      <email>aisnerjo@cinj.rutgers.edu; rizzoji@cinj.rutgers.edu; zelinsta@cinj.rutgers.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

